Clinical data | |
---|---|
Trade names | Averbol, Dianabol, Danabol, Metanabol, Naposim, Vetanabol |
Pregnancy category |
|
Routes of administration |
Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Biological half-life | 4.5–6 hours |
Excretion | Renal |
Identifiers | |
|
|
Synonyms | Methandienone; Methandrostenolone; Methandrolone; Dehydromethyltestosterone; Methylboldenone; NSC-51180; NSC-42722; 17α-Methyl-δ1-testosterone; 17α-Methylandrost-1,4-dien-17β-ol-3-one |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.000.716 |
Chemical and physical data | |
Formula | C20H28O2 |
Molar mass | 300.441 g/mol |
3D model (Jmol) | |
|
|
|
|
(what is this?) |
Metandienone (INN) (brand names Averbol, Dianabol, Danabol, Metanabol, Naposim, Vetanabol), or methandienone (BAN), also known as methandrostenolone, as well as 17α-methyl-δ1-testosterone or as 17α-methylandrost-1,4-dien-17β-ol-3-one, is an orally active, synthetic anabolic-androgenic steroid (AAS) and a 17α-methylated derivative of testosterone (specifically, the 17α-methylated derivative of boldenone (Δ1-testosterone)).
Metandienone was originally developed in 1957 by CIBA and marketed in Germany and the United States. As the CIBA product Dianabol, metandienone quickly became became the first widely used anabolic-androgenic steroid among professional and amateur athletes, and remains the most common orally-administered steroid for non-medical use.
It is currently a controlled substance in the U.S. and UK and remains popular among bodybuilders. Metandienone is readily available without a prescription in certain countries such as Mexico (under the brand name Reforvit-b), and is also manufactured in Asia and many Eastern European countries.
Metandienone was first synthesized in 1956 by researchers at the CIBA laboratories in Basel, Switzerland. CIBA filed for a US patent in 1957, and began marketing the compound as Dianabol in 1958.